Headed by project leader ERYTECH Pharma, the consortium includes Exonhit, InGen BioSciences, AP-HP (Paris Public Hospitals), Inserm (National Institute for medical research), and Paris-Diderot University. It aims at developing innovative therapies for the enzymatic treatment of chemo- or radio- resistant cancers, and tools enabling personalized care of patients.

 

Diaxonhit will be responsible for two phases of the project that utilize its hGWSA technology, which enables the study of the transcriptomic profile of tumors;

1) the identification of biomarkers of susceptibility to therapeutic response in the context of reducing the risks associated with the development of treatments, and

2) the development of an enzymatic therapy companion diagnostic that will identify responders, thus improving personalized care.

Diaxonhit is also in charge of the development of a test to monitor the direct effect of drug activity   by measuring the depletion of amino acids. The test result will allow the clinician to adjust and optimize an individual patient’s therapeutic regiment.